• Uncategorized

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing…